HC Wainwright Estimates Liquidia’s Q1 Earnings (NASDAQ:LQDA)

Liquidia Co. (NASDAQ:LQDA) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Liquidia in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Needham & Company LLC lifted their target price on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, Scotiabank upped their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Price Performance

Shares of LQDA opened at $15.66 on Monday. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.92. The stock has a market capitalization of $1.34 billion, a P/E ratio of -9.61 and a beta of 0.07. The firm’s 50 day moving average is $14.87 and its 200-day moving average is $12.27.

Insider Activity

In other news, CFO Michael Kaseta sold 23,370 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now directly owns 401,755 shares in the company, valued at $4,732,673.90. The trade was a 5.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Corebridge Financial Inc. lifted its holdings in shares of Liquidia by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after buying an additional 694 shares during the last quarter. Catalina Capital Group LLC raised its position in Liquidia by 6.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after acquiring an additional 1,125 shares in the last quarter. Cetera Investment Advisers lifted its stake in Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after acquiring an additional 1,277 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares in the last quarter. Finally, Sigma Planning Corp increased its stake in shares of Liquidia by 3.4% during the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock worth $767,000 after purchasing an additional 2,115 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).